Alzheimer’s Disease Clinical Trials

TRAILBLAZER (I5T-MC-AACI)

Description
The Booth Gardner Parkinson’s Care Center is conducting a randomized, double-blind, placebo-controlled, Phase 3 study of an investigational drug, donanemab, in patients with early symptomatic Alzheimer’s disease (AD).

Currently enrolling

Who may be eligible to participate?
Male or female subjects, 60 to 85 years of age, with gradual and progressive change in memory function reported by the participant or informant for ≥6 months. Must have study partner to participate. Other inclusion/exclusion criteria apply.

What does participation involve?
Participants who meet eligibility criteria will be randomized in a 1:1 ratio to either investigational drug -donanemab or placebo. The maximum total duration of study participation for each participant, including screening, treatment, and the post-treatment follow-up periods, is up to 127 weeks.

Investigator: Pinky Agarwal, M.D., FAAN

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com

ATH-1017-AD-0202

Description
EvergreenHealth Neuroscience Institute is conducting a phase 2, randomized, placebo-controlled study to evaluate if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease.

Currently enrolling

Who may be eligible to participate?

  • Between 55 to 85 years of age
  • Have been diagnosed with mild to moderate Alzheimer’s disease
  • Have a reliable support person or caregiver willing to participate in study visits, report on daily activities, and oversee or help with treatment administration.

Other inclusion/exclusion criteria apply.

What does participation involve?
Total participation in this study will be approximately 8 months. This includes:

  • A Screening Period of up to 28 days;
  • A Pre-baseline Period (to perform an initial assessment of a subject’s condition) of up to 5 days;
  • A Treatment Period, including Baseline (where subjects will receive their assigned study medication) of up to 26 weeks (approximately 6 months). Investigational drug will be administered by subcutaneous (SC) injection once-daily; and
  • A Post-treatment Follow-up Period (to check subjects’ overall health) of 4 weeks.

Investigator: Daniel J. Burdick, M.D.

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com

Contact Us

12039 NE 128th Street
Suite 300
Kirkland, WA 98034

Get Directions

425.899.5385  Phone

Office Hours

Mon-Fri   8 a.m. - 5 p.m.

Send Email